Qsymia 3.75mg/23mg Capsules In Pakistan And Dubai

Qsymia 3.75mg/23mg Capsules In Pakistan And Dubai - The results presented here are from the combined studies supporting FDA approval of Qsymia. The dosing schedule in those studies differ from the dosing schedule that your physician may recommend. As a result of this dosing differential, your results may vary depending on your weight, BMI, diet, activity level, dose of Qsymia, and other factors.

Qsymia was studied in 2 large trials that involved 3,754 patients 18 years and older whose BMI was 27 kg/m² or greater. For the subjects in the 2 studies the average baseline weight was 256 lbs and 227 lbs, and the average baseline waist circumference was 47 inches and 45 inches. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg (starter dose), phentermine 7.5 mg/topiramate 46 mg (recommended dose), or phentermine 15 mg/topiramate 92 mg (top dose). In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day.

Qsymia 3.75mg/23mg Capsules | Indication

Qsymia should be used together with a reduced-calorie diet and increased physical activity for chronic weight management in:

• Adults with an initial body mass index (BMI) of:
• 30 kg/m² or greater (obese) or
• 27 kg/m² or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol
• Pediatric patients aged 12 years and older with an initial BMI in the 95th percentile or greater standardized for age and sex

Qsymia 3.75mg/23mg Capsules | Cautions

Do not take Qsymia if you are pregnant, planning to become pregnant, or become pregnant during Qsymia treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking ce